Related Experiment Videos
Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients
P C Kuo1, J M Kirshenbaum, J Gordon
1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Insights
Lovastatin effectively treats hypercholesterolemia in heart transplant patients. This study shows significant cholesterol reduction with good tolerability, offering a safe option for managing post-transplant lipid levels.
Area of Science:
- Cardiology
- Pharmacology
- Transplantation Medicine
Background:
- Hypercholesterolemia is common after cardiac transplantation.
- It may contribute to accelerated coronary atherosclerosis.
- Conventional lipid-lowering drugs are often unsuitable for transplant recipients.
Purpose of the Study:
- To evaluate the safety and efficacy of lovastatin for treating hypercholesterolemia in cardiac transplant recipients.
- To assess the impact of lovastatin on lipid profiles in this patient population.
Main Methods:
- 11 cardiac transplant recipients with type II hyperlipidemia were treated with lovastatin (20-60 mg/day) for 1 year.
- Patients continued standard immunosuppression (cyclosporine-A, prednisone, azathioprine).
- Lipid profiles, liver enzymes, renal function, creatine kinase, and cyclosporine-A levels were monitored quarterly.
Main Results:
- Total cholesterol decreased by 27% and LDL cholesterol by 34% after 3 months, with sustained effects.
- Triglycerides, HDL cholesterol, liver enzymes, creatinine, creatine kinase, and cyclosporine-A levels remained stable.
- Lovastatin was well-tolerated by all patients.
Conclusions:
- Lovastatin is a safe, effective, and well-tolerated treatment for hypercholesterolemia in cardiac transplant recipients.
- It offers a viable therapeutic option for managing post-transplant dyslipidemia.
Abstract:
Hypercholesterolemia (type II hyperlipidemia) after cardiac transplantation is common and may play a role in the accelerated rate of coronary atherosclerosis seen following the procedure. However, conventional cholesterol-lowering drugs are either ineffective or contraindicated for use in transplant recipients. The presence of type II hyperlipidemia was identified in 11 cardiac transplant recipients during a mean follow-up period of 15 months (range 3 to 41) after transplantation. Lovastatin, at an initial dosage of 20 mg/day, was administered for a period of 1 year. The maximal dosage of lovastatin was 60 mg/day. All patients received maintenance dosages of immunosuppressive agents, including cyclosporine-A, prednisone and, in some instances, azathioprine. Lipid profiles, hepatic transaminases, serum creatinine, creatine kinase and cyclosporine-A serum trough levels were measured quarterly. Total cholesterol decreased by 27% (354 +/- 50 vs 258 +/- 36 mg/dl, p less than 0.01) after 3 months and remained stable thereafter. Similarly, low density lipoprotein cholesterol decreased by 34% (221 +/- 51 vs 146 +/- 40 mg/dl, p less than 0.01) after 3 months and remained constant. Triglycerides, high density lipoprotein, hepatic transaminases, creatinine, creatine kinase and trough cyclosporine-A levels remained stable during the 1-year follow-up period. Lovastatin was uniformly well tolerated in this study group. When given in modest dosages, lovastatin appears to be a safe, effective and well-tolerated therapy for hypercholesterolemia in cardiac transplant recipients.